Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Lung Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Melanoma 8Carcinoma, Non-Small-Cell Lung 6Urinary Bladder Neoplasms 5Ovarian Neoplasms 4Endometrial Neoplasms 4Carcinoma, Transitional Cell 4Triple Negative Breast Neoplasms 3Neoplasm Metastasis 3Mouth Neoplasms 3Leukemia, Myeloid, Acute 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Carcinoma 3Breast Neoplasms 3Urogenital Neoplasms 2Sezary Syndrome 2Pancreatic Neoplasms 2Neoplasms 2Mycosis Fungoides 2Mesothelioma, Malignant 2Lymphoma, Non-Hodgkin 2Lymphoma, Large B-Cell, Diffuse 2Glioma 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Renal Cell 2Carcinoma, Merkel Cell 2Biliary Tract Neoplasms 2

Interventions

pembrolizumab 1interferon gamma-1b 1Interferon-gamma 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Liposarcoma, Myxoid × pembrolizumab × Clear all
NCT03063632 2023-10-25

Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
28 enrolled 15 charts
LymphoidSarcoma

Mycosis Fungoides, Sezary Syndrome, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡